{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-23-000150","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.354667+00:00","generated_at":"2026-06-07T21:05:57.164065+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunovant reports positive IMVT-1402 600 mg Phase 1 data: 74% IgG reduction, placebo-like albumin/LDL-C","bullets":["Four weekly 600 mg SC doses of IMVT-1402 reduced total IgG by mean 74%, similar to batoclimab's 76% at 680 mg.","No significant changes in serum albumin or LDL-C at Day 29 (p>0.05), consistent with placebo-like profile.","All doses well tolerated; only mild or moderate treatment-emergent adverse events observed.","Company expects ~80% steady-state IgG reduction with continued weekly 600 mg dosing after 6-8 weeks.","Immunovant says profile supports broad portfolio of first-in-class and best-in-class FcRn indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-23-000150","json":"https://secwatch.observer/filing/0001764013-23-000150.json","markdown":"https://secwatch.observer/filing/0001764013-23-000150.md","text":"https://secwatch.observer/filing/0001764013-23-000150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000150/0001764013-23-000150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000150/imvt-20231128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:05:57.164065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}